Annals of hepatology最新文献

{"title":"Prevalence and mortality prognosis of steatotic liver disease phenotypes","authors":"Zhiyu Sun, Chi Zhou, Yiwen Zhang, Pengfei Li, Junjie Guo, Zhexun Lian, Hongwei Ji","doi":"10.1016/j.aohep.2024.101487","DOIUrl":"10.1016/j.aohep.2024.101487","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 3","pages":"Article 101487"},"PeriodicalIF":3.8,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002813/pdfft?md5=0ebcf89a68a8e5cd26f36ad80f76e9fd&pid=1-s2.0-S1665268124002813-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139956846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study","authors":"Ana Barreira-Díaz ,&nbsp;Mar Riveiro-Barciela ,&nbsp;Eva María Fernández-Bonilla ,&nbsp;Vanesa Bernal ,&nbsp;Agustín Castiella ,&nbsp;Marta Casado-Martín ,&nbsp;Carolina Delgado ,&nbsp;María-Carlota Londoño ,&nbsp;Álvaro Díaz-González ,&nbsp;Indhira Pérez-Medrano ,&nbsp;Andrés Conthe ,&nbsp;Margarita Sala ,&nbsp;Beatriz Mateos ,&nbsp;Judith Gómez-Camarero ,&nbsp;Dolores Antón-Conejero ,&nbsp;Carmen Del Pozo-Calzada ,&nbsp;Francisca Cuenca ,&nbsp;Ares Villagrasa-Vilella ,&nbsp;Magdalena Salcedo","doi":"10.1016/j.aohep.2024.101489","DOIUrl":"10.1016/j.aohep.2024.101489","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Different patterns of liver injury have been reported in association with the SARS-CoV-2 vaccines. The aim of this study was to describe a nationwide cohort of patients with SARS CoV-2 vaccine-induced liver injury, focusing on treatment and the evolution after further booster administration.</p></div><div><h3>Patients and Methods</h3><p>multicentre, retrospective-prospective study, including subjects who developed abnormal liver tests within 90 days after administration of SARS-CoV-2 vaccination.</p></div><div><h3>Results</h3><p>47 cases were collected: 17 after prime dose and 30 after booster. Age was 57 years, 30 (63.8 %) were female, and 7 (14.9 %) had a history of prior autoimmune hepatitis (AIH). Most cases were non-severe, though 9 (19.1 %) developed acute liver injury or failure (ALF). Liver injury tended to be more severe in those presenting after a booster (p=0.084). Pattern of liver injury was hepatocellular (80.9 %), mixed (12.8 %) and 3 (6.4 %) cholestatic. Liver biopsy was performed on 33 patients; 29 showed findings of AIH. Forty-one (87.2 %) patients received immunosuppressants, mostly corticosteroids (35/41). One required liver transplantation and another died due to ALF. Immunosuppression was discontinued in 6/41 patients without later rebound. Twenty-five subjects received at least one booster and 7 (28.0 %) relapsed from the liver injury, but all were non-severe. Recurrence was less frequent among patients on immunosuppressants at booster administration (28.6 % vs. 88.9 %, p=0.007).</p></div><div><h3>Conclusions</h3><p>SARS CoV-2 vaccine-induced liver injury is heterogeneous but mostly immune-mediated. Relapse of liver injury after re-exposure to vaccine is frequent (28.0 %) but mild. Immunosuppression at booster administration is associated with a lower risk of liver injury.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 3","pages":"Article 101489"},"PeriodicalIF":3.8,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002837/pdfft?md5=36ea7deb417f9deb5e451e0d250de437&pid=1-s2.0-S1665268124002837-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139954983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?","authors":"Luciana Agoglia ,&nbsp;Ana Carolina Cardoso ,&nbsp;Lívia Barbosa ,&nbsp;Cecília Schubert Xavier Lagalhard Victer ,&nbsp;Sueli Carneiro ,&nbsp;Paulo Henrique Condeixa de França ,&nbsp;Maria Chiara Chindamo ,&nbsp;Cristiane Alves Villela-Nogueira","doi":"10.1016/j.aohep.2024.101477","DOIUrl":"10.1016/j.aohep.2024.101477","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>A high prevalence of steatotic liver disease has been described in psoriasis. However, the influence of genetic polymorphisms has yet to be investigated in this scenario. This study aims to determine the frequency of steatosis, advanced liver fibrosis and PNPLA3/TM6SF2 genotypes in individuals with psoriasis and to evaluate the impact of genetic polymorphisms, metabolic parameters and cumulative methotrexate dose on steatosis and fibrosis.</p></div><div><h3>Materials and Methods</h3><p>Cross-sectional study that prospectively included psoriasis outpatients, submitted to clinical and laboratory analysis, transient elastography (FibroScan®, Fr) and PNPLA3/TM6SF2 genotyping. Steatosis was defined by CAP ≥275 dB/m and advanced liver fibrosis as transient elastography ≥10 kPa. Logistic regression analysis evaluated the independent variables related to steatosis and fibrosis; p-value&lt; 0.05 was considered significant.</p></div><div><h3>Results</h3><p>One hundred and ninety-nine patients were enrolled (age 54.6 ± 12.6 years, 57.3% female). Metabolic syndrome (MetS), steatosis and advanced liver fibrosis prevalence were 55.8%, 54.8% and 9%, respectively. PNPLA3 and TM6SF2 genotypes frequencies were CC 42.3%/CG 49.5%/GG 8.2% and CC 88.7%/ CT 11.3%/ TT 0%. MetS (OR3.01 95%CI 1.51-5.98; <em>p = 0.002</em>) and body mass index (OR1.17 95%CI 1.08-1.26; <em>p &lt; 0.01</em>) were independently associated with steatosis. Diabetes Mellitus (T2DM) (OR10.76 95%CI 2.42-47.87; <em>p = 0.002</em>) and harboring at least one PNPLA3 G allele (OR5.66 95%CI 1.08-29.52; <em>p = 0.039</em>) were associated with advanced fibrosis, but not TM6SF2 polymorphism or cumulative MTX dose.</p></div><div><h3>Conclusions</h3><p>MetS and T2DM confer higher odds for steatosis and advanced fibrosis in individuals with psoriasis. PNPLA3 G allele, but not TM6SF2 polymorphism, impacts a 5-fold odds of advanced liver fibrosis.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101477"},"PeriodicalIF":3.8,"publicationDate":"2024-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002710/pdfft?md5=9e23ab24cdd19547737fae8e45ba211a&pid=1-s2.0-S1665268124002710-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139740208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occult liver disease: A multinational perspective","authors":"Paulina Vidal-Cevallos ,&nbsp;Nayelli Flores-García ,&nbsp;Norberto C. Chávez-Tapia ,&nbsp;Naga P. Chalasani","doi":"10.1016/j.aohep.2024.101480","DOIUrl":"10.1016/j.aohep.2024.101480","url":null,"abstract":"<div><p>Occult liver disease refers to the presence of unrecognized chronic liver disease and cirrhosis. Liver disease is currently the eleventh cause of death globally, representing 4% of all deaths in the world. Alcohol consumption is the leading cause of cirrhosis globally, accounting for approximately 60% of cases. The estimated global prevalence of non-alcoholic fatty liver disease (NAFLD) is 32.4% and has been steadily increasing over the last years. Viral hepatitis B and C accounted for 1.3 million deaths in 2020.</p><p>Several studies in populations at high risk of chronic liver disease (elevated liver enzymes, type 2 diabetes, excessive alcohol consumption) have found an elevated prevalence of occult liver disease. Attempts should be made to assess the prevalence of occult liver disease in Latin America, a region with one of the highest rates of metabolic diseases and excessive alcohol consumption.</p><p>Screening for NAFLD in high-risk subjects and screening for excessive drinking and alcohol use disorders at every level of medical care is relevant. Efforts should also focus on the early treatment of occult liver disease to try to reduce liver disease burden and, in the case of occult viral hepatitis infection, prevent further spreading.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 3","pages":"Article 101480"},"PeriodicalIF":3.8,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002746/pdfft?md5=8affd1faac723baad35a2d49feb4c0d6&pid=1-s2.0-S1665268124002746-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinopathy as a predictive indicator for significant hepatic fibrosis according to T2DM status: A cross-sectional study based on the national health and nutrition examination survey data","authors":"Jinze Li ,&nbsp;Yi Xiang ,&nbsp;Jiahao Han ,&nbsp;Youfang Gao ,&nbsp;Ruiying Wang ,&nbsp;Zihe Dong ,&nbsp;Huihui Chen ,&nbsp;Ruixia Gao ,&nbsp;Chuan Liu ,&nbsp;Gao-Jun Teng ,&nbsp;Xiaolong Qi","doi":"10.1016/j.aohep.2024.101478","DOIUrl":"10.1016/j.aohep.2024.101478","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Type 2 Diabetes Mellitus (T2DM), a prevalent metabolic disorder, often coexists with a range of complications, with retinopathy being particularly common. Recent studies have shed light on a potential connection between diabetic retinopathy (DR) and hepatic fibrosis, indicating a possible shared pathophysiological foundation in T2DM. This study investigates the correlation between retinopathy and hepatic fibrosis among individuals with T2DM, as well as evaluates the diagnostic value of DR for significant hepatic fibrosis.</p></div><div><h3>Materials and Methods</h3><p>Our cross-sectional analysis incorporated 5413 participants from the National Health and Nutrition Examination Survey (NHANES) 2005-2008. The Fibrosis-4 score (FIB-4) classified hepatic fibrosis into different grades (F0-F4), with significant hepatic fibrosis marked as F2 or higher. Retinopathy severity was determined using retinal imaging and categorized into four levels. The analysis of variance or Chi-square tests facilitated group comparisons. Additionally, the receiver operating characteristic (ROC) analysis appraised the predictive accuracy of retinopathy for significant hepatic fibrosis in the T2DM population.</p></div><div><h3>Results</h3><p>Among 5413 participants, the mean age was 59.56 ± 12.41, with 50.2% male. And 20.6% were diagnosed with T2DM. Hepatic fibrosis grading was positively associated with retinopathy severity (OR [odds ratio]: 1.521, 95%CI [confidence interval]: 1.152-2.008, <em>P</em> = 0.003) across the entire population. The association was amplified in the T2DM population according to Pearson's analysis results. The ROC curve demonstrated retinopathy's diagnostic capacity for significant hepatic fibrosis in the T2DM population (AUC [area under curve] = 0.72, 95%CI: 0.651-0.793, <em>P</em> &lt; 0.001).</p></div><div><h3>Conclusions</h3><p>Retinopathy could serve as an independent predictor of significant hepatic fibrosis in T2DM population. Ophthalmologists are advised to closely monitor T2DM patients with retinopathy.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101478"},"PeriodicalIF":3.8,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002722/pdfft?md5=363fd1f654035b5ceb33008f664e6451&pid=1-s2.0-S1665268124002722-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver fibrosis: More than meets the eye","authors":"Amedeo Lonardo","doi":"10.1016/j.aohep.2024.101479","DOIUrl":"10.1016/j.aohep.2024.101479","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101479"},"PeriodicalIF":3.8,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002734/pdfft?md5=d7014d696fd868144598a1f425ddf087&pid=1-s2.0-S1665268124002734-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139721259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The 2023 meeting of the latin American association for the study of the liver: A summary and looking ahead","authors":"Francisco Javier Valentin-Cortez,&nbsp;Norberto Chávez-Tapia","doi":"10.1016/j.aohep.2024.101476","DOIUrl":"10.1016/j.aohep.2024.101476","url":null,"abstract":"","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 3","pages":"Article 101476"},"PeriodicalIF":3.8,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002709/pdfft?md5=924b84df08b990cfef0764b4a77ea0fb&pid=1-s2.0-S1665268124002709-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139715746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of preoperative nonselective beta-blocker use on acute kidney injury after living donor liver transplantation: Propensity score analysis","authors":"Hye-Won Jeong ,&nbsp;Jae Hwan Kim ,&nbsp;Sang-bin Han ,&nbsp;Hye-Mee Kwon ,&nbsp;In-Gu Jun ,&nbsp;Jun-Gol Song ,&nbsp;Gyu-Sam Hwang","doi":"10.1016/j.aohep.2024.101474","DOIUrl":"10.1016/j.aohep.2024.101474","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Acute kidney injury (AKI) is prevalent and has deleterious effects on postoperative outcomes following liver transplantation (LT). The impact of nonselective beta-blockers (NSBBs) in patients with liver cirrhosis remains controversial. This study investigated the association between preoperative NSBB use and AKI after living donor LT (LDLT).</p></div><div><h3>Patients and Methods</h3><p>We evaluated 2,972 adult LDLT recipients between January 2012 and July 2022. The patients were divided into two groups based on the preoperative NSBB use. Propensity score matched (PSM) and inverse probability of treatment weighting (IPTW) analyses were performed to evaluate the association between preoperative NSBB use and postoperative AKI. Multiple logistic regression analyses were also used to identify the risk factors for AKI.</p></div><div><h3>Results</h3><p>The overall incidence of AKI was 1,721 (57.9%) cases. The NSBB group showed a higher incidence of AKI than the non-NSBB group (62.4% vs. 56.7%; <em>P</em> = 0.011). After PSM and IPTW analyses, no significant difference in the incidence of AKI was found between the two groups (Odds ratio, OR 1.13, 95% confidence interval, CI 0.93–1.37, <em>P</em> = 0.230, PSM analysis; OR 1.20, 95% CI 0.99–1.44, <em>P</em> = 0.059, IPTW analysis). In addition, preoperative NSBB use was not associated with AKI after multivariate logistic regression analysis (OR 1.16, 95% CI 0.96–1.40, <em>P</em> = 0.118).</p></div><div><h3>Conclusions</h3><p>Preoperative NSBB use was not associated with AKI after LDLT. Further studies are needed to validate our results.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101474"},"PeriodicalIF":3.8,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002680/pdfft?md5=880a1abe5d0ed09fe396b4298e05fb20&pid=1-s2.0-S1665268124002680-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139705880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5/ROS pathway","authors":"Shengguang Yan ,&nbsp;Lina Yu ,&nbsp;Ziren Chen ,&nbsp;Dan Xie ,&nbsp;Zuli Huang ,&nbsp;Shi Ouyang","doi":"10.1016/j.aohep.2024.101475","DOIUrl":"10.1016/j.aohep.2024.101475","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Acute liver injury (ALI) is characterized by massive hepatocyte death with high mortality and poor prognosis. Hepatocyte pyroptosis plays a key role in the physiopathological processes of ALI, which can damage mitochondria and release NLRP3 inflammasome particles, causing systemic inflammatory responses. Z-DNA Binding Protein 1 (ZBP1) is a sensor that induces cell death. Here, we investigated whether ZBP1 participates in hepatocyte pyroptosis and explored the possible pathogenesis of ALI.</p></div><div><h3>Materials and Methods</h3><p>Hepatocyte pyrotosis was induced with lipopolysaccharide (LPS) and nigericin (Nig), and the expression of <em>Zbp1</em> (<em>ZBP1</em>) was examined by western blot analysis and RT-qPCR. Further, we transfected AML-12 (LO2 and HepG2) cell lines with <em>Zbp1</em> (<em>ZBP1</em>) siRNA. After ZBP1 was silenced, LDH release and flow cytometry were used to measure the cell death; Western blot analysis and RT-qPCR were used to detect the marker of NLRP3 inflammasome activation and pyroptosis. We also detected the expression of mitochondrial linear rupture marker phosphoglycerate mutase family member 5 (PGAM5) using western blot analysis and reactive oxygen species (ROS) using the DCFH-DA method.</p></div><div><h3>Results</h3><p>The expression of ZBP1 was up-regulated in LPS/Nig-induced hepatocytes. Si-<em>Zbp1</em> (Si-<em>ZBP1</em>) inhibited NLRP3 inflammasome activation and pyroptosis in LPS/Nig-induced hepatocytes. Moreover, ZBP1 silencing inhibited the expression of PGAM5 by reducing ROS production.</p></div><div><h3>Conclusions</h3><p>ZBP1 promotes hepatocellular pyroptosis by modulating mitochondrial damage, which facilitates the extracellular release of ROS.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 4","pages":"Article 101475"},"PeriodicalIF":3.8,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002692/pdfft?md5=1c1c3e7c746f6b0d579e1f3b60ebfe61&pid=1-s2.0-S1665268124002692-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139705881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"O- 23 STRATEGIES TO ELIMINATE HEPATITIS C VIRUS INFECTION IN THE AMERICAS","authors":"Luis Antonio Díaz ,&nbsp;Sergio García ,&nbsp;Rayan Khan ,&nbsp;Gustavo Ayares ,&nbsp;Javier Uribe ,&nbsp;Francisco Idalsoaga ,&nbsp;José Miguel Fuentealba ,&nbsp;Eduardo Fuentes ,&nbsp;Katherine Maldonado ,&nbsp;Mariana Lazo ,&nbsp;Catterina Ferreccio ,&nbsp;Manuel Mendizabal ,&nbsp;Melisa Dirchwolf ,&nbsp;Patricia Guerra ,&nbsp;Claudia P. Oliveira ,&nbsp;Mario Guimarães ,&nbsp;Mario Reis ,&nbsp;Giada Sebastiani ,&nbsp;Mayur Brahmania ,&nbsp;Alnoor Ramji ,&nbsp;Juan Pablo Arab","doi":"10.1016/j.aohep.2023.101273","DOIUrl":"https://doi.org/10.1016/j.aohep.2023.101273","url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Although the WHO strategy aims to eliminate the hepatitis C virus (HCV) as a public health threat by 2030, national strategies are variable worldwide. This study aimed to assess the establishment of different policies and strategies to eliminate HCV in the Americas.</p></div><div><h3>Materials and Methods</h3><p>We conducted a 23-item survey about HCV-related policies and strategies among gastroenterologists and hepatologists in the Americas. The survey was carried out electronically (2022–2023). Data were compared with governmental institutions, regulatory agencies, scientific societies, and scientific publications. We estimated an index obtained from a regression scoring method through exploratory analysis, and row values were normalized from 0 to 100.</p></div><div><h3>Results</h3><p>We obtained 52 responses from 19 countries. The median HCV-related policies index was 51.4 [IQR:27.3–70.1]. The lower establishment of HCV-related policies was observed in Ecuador (0.0), Honduras (6.6), and Costa Rica (9.8), while the highest performance was observed in Argentina (94.1), Colombia (94.7), and Canada (100)(Figure 1A). Fifteen (78.9%) countries have adopted a national strategic plan to eliminate HCV. Three (15.8%) countries have universal screening for HCV infection (Figure 1B). After a positive HCV serological test, 10 (52.6%) countries perform reflex testing to confirm HCV diagnosis using the same sample. However, only 7 (36.8%) countries have an alert system for the requesting physician. Twelve (63.2%) countries have a direct referral system for specialized care of HCV-positive cases. Universal access to direct-acting antivirals (DAAs) exists in 15 (78.9%) countries. Universal access to DAAs was not widely available in Cuba, Ecuador, Venezuela, and the United States. Seven (36.8%) countries have generic DAAs available. Only 3 (15.8%) countries performed a retrospective search for HCV-positive cases that could have been lost to follow-up.</p></div><div><h3>Conclusions</h3><p>Although most countries have adopted a national strategic plan to eliminate HCV, there are several issues and barriers to elimination in the Americas.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":"29 ","pages":"Article 101273"},"PeriodicalIF":3.8,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003769/pdfft?md5=fdccb539e43091b204418b3e3e514f13&pid=1-s2.0-S1665268123003769-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139975583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}